Etrolizumab is a humanized IgG1 kappa monoclonal antibody targeting the β7 subunit of gastrointestinal α4β7 and αEβ7 integrins, under investigation for ulcerative colitis and Crohn's disease treatment. The DrugMonitor™ Anti-Etrolizumab Antibody (VS-1224-YC456) is an anti-drug antibody (ADA) against Etrolizumab. This drug-based antibody is raised in mice immunized with the Etrolizumab. The anti-Etrolizumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Etrolizumab in samples.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Anti-Human Integrin alpha 4 beta 7 Recombinant Antibody (Etrolizumab)Recombinant monoclonal antibody to integrin alpha 4 beta 7. Etrolizumab is a humanized monoclonal antibody designed for the treatment of inflammatory bowel disease.
Afuco™ Anti-ITGA4 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-135)This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to integrin alpha 4 beta 7. It is a humanized monoclonal antibody designed for the treatment of inflammatory bowel disease.
There are currently no Customer reviews or questions for VS-1224-YC456. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.